In conclusion, these recent studies strongly support CD123 as an important therapeutic target for the treatment of BPDCN, while a possible in the treatment of AML and other hematological malignancies will have to be evaluated by in the ongoing clinical studies. The gene discussed is IL3RA; the disease is CD4+/CD56+ hematodermic neoplasm.